NCT04783597Recruiting
Early Prediction of Preeclampsia Using arteriaL Stiffness in High-risk prEgnancies
Early Prediction of Preeclampsia Using arteriaL Stiffness in High-risk prEgnancies; a Multinational Study (PULSE)
Source: ClinicalTrials.gov · Last updated 18 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Despite advances in obstetric care, preeclampsia (PE) remains the leading cause of maternal death and disability in both developed and developing countries, contributing to over 70,000 maternal and 500,000 fetal deaths annually worldwide. PULSE was designed using a preventative medicine approach, focusing on improving early detection of PE as opposed to managing symptoms after onset. The study aims to uncover the earliest possible signs of PE using a combination of novel clinical tools and established diagnostic techniques to better identify, track, and manage high risk pregnant women. Specifically, PULSE will be examining the incorporation of a non-invasive test for the measurement of arterial stiffness, which has been shown to be predictive of hypertensive disorders. This test, in combination with a wide range of blood biomarkers, detailed ultrasound imaging, and a comprehensive battery of physical and mental health questionnaires, represents the largest, most comprehensive preventative PE study to date. The results of this work has the potential to revolutionize the way PE and other hypertensive disorders of pregnancy are managed and treated and can serve to inform the design of future preventative clinical research studies.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2400 (estimated)
- First submitted
- 25 Feb 2021
- Start date
- 12 Jul 2021
- Primary completion date
- Jan 2026
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- NCT number
- NCT04783597
What you commit to
- Study type: Observational
- Planned participants: 2400
- From 12 Jul 2021 to the primary completion date, Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of heart disease, stroke, or peripheral arterial disease
- Infectious diseases/conditions, such as Hepatitis B/C, HIV, and COVID19
Other
- \>14 weeks gestation
- Multiple pregnancy
Who the study is looking for
- Singleton pregnancy
- Presence of at least 1 high-risk factor or 2 moderate-risk factors for pre-eclampsia
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Royal Victoria Hospital Coordinator of this site? Confirm its status | Montreal | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.